Abstract Details

Title National Estimates Of Recurrent Intracranial Hemorrhage Among Patients With Ruptured Intracranial Aneurysms

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P13 - Poster Session 13 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-002

Objective To determine the rates of recurrent intracranial hemorrhage related hospitalization within 3 month posthospitalization for treatment of ruptured intracranial aneurysm in a nationwide cohort of patients admitted for subarachnoid hemorrhage (SAH).

Background The estimates of recurrent intracranial hemorrhage in the post-hospitalization period among patients treated for ruptured intracranial aneurysms are not available outside clinical trials.

Design/Methods We identified all readmissions related to new SAH or intracerebral hemorrhage in the nationally representative data for all patients hospitalized for SAH using the Nationwide Readmissions Database (NRD) 2013 and 2014 who had undergone endovascular or surgical treatment. Cox proportional hazards analysis was used to assess the relative risk (RR) of recurrent intracranial hemorrhage for patients in treatment cohorts after adjusting for potential confounders. The 1-year survival was estimated for both treatment groups by using the Kaplan-Meier survival method.

Results A total of 8,619 patients with SAH were treated with either endovascular (n = 4,102, 47.6%) or surgical treatment (n =4,517; 52.4%).. The estimated 3 months recurrent intracranial hemorrhage survival was 99.4% and 98.4% in patients who underwent surgical and endovascular treatments, respectively (p=0.0024). After adjusting for age>65, and APDRG severity score, the RRs of recurrent any intracranial hemorrhage was higher with endovascular treatment (RR, 3.0; 95% confidence interval (CI), 1.4 -6.7 p=0.0052).

Conclusions Although the rates of recurrent intracranial hemorrhage related hospitalization were low among patients with ruptured intracranial aneurysms, there was a higher rate among patients treated with endovascular treatment.

Authors/Disclosures
PRESENTER	No disclosure on file
Saqib A. Chaudhry, MD	Dr. Chaudhry has nothing to disclose.
	No disclosure on file
	No disclosure on file
Yun Fang	No disclosure on file
Ameer Hassan, DO (Valley Baptist Medical Center)	Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Stryker. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Penumbra. Dr. Hassan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viz.ai. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Hassan has received research support from GE Healthcare.
Sairah Bashir, MD, F�鶹��ýӳ��	Dr. Bashir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic .
	No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.

�鶹��ýӳ��

�鶹��ýӳ��